Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3474724 | Italian Journal of Medicine | 2011 | 4 Pages |
Abstract
In our opinion this case is of great interest because: 1) it is the first report of a virological response in a HBV/HCV-coinfected CH patient treated with PEG-IFN; 2) control of the two viral infections was achieved with a new therapeutic strategy that included two phases: a) HBV-DNA loss at 6 months and HBsAg/anti-HBs seroconversion between months 24 and 36, after PEG-IFNα2b mono-therapy, which was administered when the HCV replication seemed to prevail over that of HBV; b) ETR for HCV after 72 weeks of PEG-IFNα2a+ribavirin, which was continued in spite of the lack of an EVR, as this does not preclude the possibility of a SVR.
Keywords
HCV-RNASVRIFNαhepatitis B “e” antigenRVRETRALTEVRHBeAgHBsAgPEG-IFNHBV-DNAASTAlpha-interferonHepatitis B surface antigenRibavirinCoinfectionHBVHepatitis C virusHCVChronic hepatitispolymerase chain reactionPCRHepatitis B virus (HBV)Hepatitis C virus (HCV)hepatitis B virusRapid virological responsesustained virological responseearly virological response
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Antonio Salvio, Maria Varriale, Tito d'Errico, Gennaro De Siena, Mario Visconti,